78 related articles for article (PubMed ID: 1619317)
21. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).
Goldray D; Weisman Y; Jaccard N; Merdler C; Chen J; Matzkin H
J Clin Endocrinol Metab; 1993 Feb; 76(2):288-90. PubMed ID: 7679397
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.
Makita K; Ishitani K; Ohta H; Horiguchi F; Nozawa S
J Bone Miner Metab; 2005; 23(5):389-94. PubMed ID: 16133689
[TBL] [Abstract][Full Text] [Related]
23. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
24. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
Newhall-Perry K; Holloway L; Osburn L; Monroe SE; Heinrichs L; Henzl M; Marcus R
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):824-9. PubMed ID: 7573251
[TBL] [Abstract][Full Text] [Related]
25. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
Taga M; Minaguchi H
Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
[TBL] [Abstract][Full Text] [Related]
26. Hormone treatment related bone mineral content changes in Japanese women with endometriosis.
Fukushima M; Shindo M; Sato K
Asia Oceania J Obstet Gynaecol; 1993 Sep; 19(3):299-307. PubMed ID: 8250765
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropin releasing hormone agonist therapy and its effect on bone mass.
Nencioni T; Penotti M; Barbieri-Carones M; Ortolani S; Trevisan C; Polvani F
Gynecol Endocrinol; 1991 Mar; 5(1):49-56. PubMed ID: 1910246
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of the effect of premenopausal oophorectomy on bone mineral content].
Ueno N; Kato Y; Masuda R; Amano K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):308-12. PubMed ID: 2786541
[TBL] [Abstract][Full Text] [Related]
29. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
[TBL] [Abstract][Full Text] [Related]
30. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis.
Matsuo H
Fertil Steril; 2004 Jan; 81(1):149-53. PubMed ID: 14711558
[TBL] [Abstract][Full Text] [Related]
31. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.
Ylikorkala O; Nilsson CG; Hirvonen E; Viinikka L
Gynecol Endocrinol; 1990 Dec; 4(4):251-60. PubMed ID: 2150580
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist.
Wang Y; Yano T; Kikuchi A; Yano N; Matsumi H; Ando K; Kasai Y; Watanabe M; Okagaki R; Osuga Y; Taketani Y
J Endocrinol; 2000 May; 165(2):467-73. PubMed ID: 10810310
[TBL] [Abstract][Full Text] [Related]
33. A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment.
Mukherjee T; Barad D; Turk R; Freeman R
Am J Obstet Gynecol; 1996 Jul; 175(1):105-9. PubMed ID: 8694034
[TBL] [Abstract][Full Text] [Related]
34. Serum osteocalcin and calcitropic hormones in a homogeneous group of patients with rheumatoid arthritis: its implication in the osteopenia of the disease.
Rico H; Revilla M; Alvarez de Buergo M; Villa LF
Clin Exp Rheumatol; 1993; 11(1):53-6. PubMed ID: 8453799
[TBL] [Abstract][Full Text] [Related]
35. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.
Matta WH; Shaw RW; Hesp R; Evans R
Clin Endocrinol (Oxf); 1988 Jul; 29(1):45-51. PubMed ID: 3150319
[TBL] [Abstract][Full Text] [Related]
36. Effect of testosterone on bone in hypogonadal males.
Isaia G; Mussetta M; Pecchio F; Sciolla A; di Stefano M; Molinatti GM
Maturitas; 1992 Aug; 15(1):47-51. PubMed ID: 1528131
[TBL] [Abstract][Full Text] [Related]
37. Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists.
Gnoth CH; Gödtke K; Freundl G; Godehardt E; Kienle E
Gynecol Obstet Invest; 1999; 47(1):37-41. PubMed ID: 9852390
[TBL] [Abstract][Full Text] [Related]
38. The influence of severe bone loss on mitral annular calcification in postmenopausal osteoporosis of elderly Japanese women.
Sugihara N; Matsuzaki M
Jpn Circ J; 1993 Jan; 57(1):14-26. PubMed ID: 8437338
[TBL] [Abstract][Full Text] [Related]
39. Correlations between bone metabolism biomarkers and fluoride exposure in adults and children.
Yang S; Yu S; Du Y; Feng Z; Jiao X; Li Q; Wu J; Sun L; Zuo J; Fu X; Li Z; Huang H; Zhou G; Yu F; Ba Y
J Trace Elem Med Biol; 2024 Jul; 84():127419. PubMed ID: 38461620
[TBL] [Abstract][Full Text] [Related]
40. Effect of treatment with GnRH agonists on new markers of bone metabolism.
Kukuvitis A; Bildiris J; Prapas Y; Tsamis D; Papadimas J; Dimitriadou A; Vlassis G
Gynecol Obstet Invest; 1999; 47(3):194-6. PubMed ID: 10087416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
